- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00511277
Efficacy and Safety of Quetiapine in Treating Affective Symptoms of Patients With First-episode psychosis-a Pilot Study
Single-arm, Open-label and Multicenter Phase IV Study: Efficacy and Safety of Quetiapine in Treating Affective Symptoms of Patients With First-episode Psychosis - a Pilot Study
The purpose of this study is:
To investigate whether a treatment with quetiapine for six months in patients with first-episode psychosis may be effective in treating depressive symptoms.
To investigate whether a treatment with quetiapine for six months in patients with first-episode psychosis may be effective in mania-like symptoms and to evaluate the general efficacy in psychopathology as well as the safety and tolerability of quetiapine.
Study Overview
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Göttingen, Germany
- Department of Psychiatry and Psychotherapy, GEORG-AUGUST-UNIVERSITY GÖTTINGEN
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
All patients who meet the following inclusion criteria are eligible to participate in the study:
- male and female patients with first-episode schizophrenia (based on ICD-10 criteria)
- in- and out-patients
- age between 18 and 45
- verbal IQ 85
- given written informed consent
Exclusion Criteria:
Patients who meet one or more of the following exclusion criteria cannot participate in the study:
- Other Psychiatric disorders not in full remission, concomitant organic mental disorder or mental retardation
- Patients who, in the investigators judgement, pose an imminent risk of suicide or a danger to self or others
- Hamilton Depression Rating Scale<7 points
- Female patients who are pregnant, lactating or at risk of pregnancy
- Female patients who are not using a highly effective method of birth control. A highly effective method of birth control is defined as those which results in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as implantants, injectables, combined oral contraceptives, some IUDs, sexual abstinence or vasectomised partner. For subjects using a hormonal contraceptive method, information regarding the product under investigation and its potential effect on the contraception must be addressed.
- history of idiopathic orthostatic hypotension, or condition that would predispose to (dehydration, hypovolaemia)
- Risk of transmitting human immunodeficiency virus (HIV) or hepatitis B and C, via blood or other body fluids
- history of non-compliance as judged by the investigator
- Patients with substance dependence. A urine drug screen will be performed. The investigator will evaluate the results along with medical history to determine if the patient meets the DSM-IV criteria for substance dependence
Patients with known diabetes mellitus or impaired glucose tolerance, especially a patient with Diabetes Mellitus (DM) fulfilling one of the following criteria:
- unstable DM defined as enrollment glycosylated hemoglobin (HbA1c)>8.5%
- patients admitted to hospital for treatment of DM or DM related illness in past 12 weeks
- patients not under physicians care for DM
- physicians responsible for patient´s DM care has not indicated that patient´s DM is controlled
- physician responsible for patient´s DM care has not approved patient´s participation in the study
- patient has not been on the same dose of oral hypoglycemic drug(s) and/or diet for the 4 weeks prior to randomization. (For thiazolidinediones (glitazones) this period should not be less than 8 weeks)
- patients taking insulin whose daily dose on one occasion in the past 4 weeks has been more than 10% above or below their mean dose in the preceding 4 weeks.
Note: If a diabetic patient meets one of these criteria, the patient is to be excluded even if the treating physician believes that the patient is stable and can participate in the study.
- ECG considered to show clinical significant abnormalities at enrolment as determined by a cardiologist
- Use of drugs that induce or inhibit the hepatic metabolizing cytochrome 3A4 enzyme within 2 weeks prior to randomization (e.g. inducers: phenytoin, carbamazepine, phenobarbital, rifampicin, rifabutin, glucocorticoids, thioridazine and St. Johns´wort (=Johanniskraut) and inhibitors: ketaconazole (except for topical use), itraconazole, fluconazole, erythromycin, clarithromycin, fluvoxamine, nefazodone, troleandomycin, indinavir, nelfinavir and saquinavir).
- patients with insufficient knowledge of the German language
- A thyroid-stimulating hormone (TSH) concentration more than 10% above the upper limit of the normal range and the laboratory used for sample analysis at enrolment, whether or not the subject is being treated for hypothyroidism
- Any serious and unstable somatic illness (e.g. malignant tumor, severe cardiovascular disease, etc.) that, in the opinion of the investigator, would be negatively affected by the study medication or that would affect study medication. If relevant medical findings are obtained during the examination, it is at the physician's discretion to initiate additional examinations (e.g. lab testing, ECG). If medically indicated examinations have already been carried out, the results should not be older than two weeks at the time of the screening visit. The patient can only participate in the study if all study results are within the normal range or the examiner has determined a deviation as clinically irrelevant. This should be clearly documented in the CRF.
- Participation in another drug trial within 4 weeks prior to enrolment into this study or longer in accordance with local requirements
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Changes in the Hamilton Depression Rating Scale (HAMDS) from Baseline to Endpoint
Time Frame: treatment for six months
|
treatment for six months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Changes in the Young Mania Rating Scale,Changes in the Positive and Negative Syndrome Scale,Changes in the Clinical Global Impression Scale(CGI,Changes in the self assessment of depressive symptoms(Beck Depression Inventory) from Baseline to Endpoint.
Time Frame: for six months
|
for six months
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Peter Falkai, MD PhD, Department of Psychiatry and Psychotherapy, GEORG-AUGUST-UNIVERSITY GÖTTINGEN, GERMANY
- Principal Investigator: Thomas Wobrock, MD PhD, Department of Psychiatry and Psychotherapy, GEORG-AUGUST-UNIVERSITY GÖTTINGEN, GERMANY
- Principal Investigator: Andreas Heinz, MD PhD, Department of Psychiatry and Psychotherapy, Charité Campus Mitte Berlin, Germany
- Principal Investigator: Georg Juckel, MD PhD, Department of Psychiatry, Ruhr University Bochum, Germany
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Schizophrenia Spectrum and Other Psychotic Disorders
- Schizophrenia
- Psychotic Disorders
- Mental Disorders
- Affective Symptoms
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Antidepressive Agents
- Quetiapine Fumarate
Other Study ID Numbers
- D1449L00016
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Peking UniversityNot yet recruitingTreatment-resistant Schizophrenia
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
-
NYU Langone HealthNot yet recruitingTreatment-resistant SchizophreniaUnited States
Clinical Trials on Seroquel®
-
AstraZenecaCompletedSchizophreniaItaly, Germany, Austria, Spain, Denmark
-
AstraZenecaCompletedMajor Depressive DisorderBelgium
-
Dr Alexander McIntyre Inc.CompletedMajor Depression With Comorbid Anxiety SymptomsCanada
-
Institut fuer anwendungsorientierte Forschung und...CompletedAlcohol Drinking | Alcoholism | Alcohol Consumption | Alcohol Abuse | Alcohol Relapse PreventionGermany
-
Indiana University School of MedicineAstraZenecaCompleted
-
BC Women's Hospital & Health CentreCompletedPostpartum DepressionCanada
-
Sunnybrook Health Sciences CentreAstraZenecaCompletedDepressive Disorder, MajorCanada
-
AstraZenecaTerminated
-
AstraZenecaCompleted